Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis

Learn more about:
Related Clinical Trial
Epidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury Retraining Walking After Spinal Cord Injury Spinal Cord Injury Exercise and Nutrition Conceptual Engagement Body Composition Assessment in Spinal Cord Injury Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study Medico-economical Impact of the Brindley Neurosurgical Technique in France Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis The Safety of ahSC in Chronic SCI With Rehabilitation Evaluation of an Advanced Lower Extremity Neuroprostheses Natural History of Shoulder Pathology in Manual Wheelchair Users Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury Spinal Cord Injury Leg Rehabilitation Multimodal Exercises to Improve Leg Function After Spinal Cord Injury A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes A Neuroprosthesis for Seated Posture and Balance Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI) Functional Electrical Stimulation Cycling in SCI Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury Exercise to Reduce Obesity in Spinal Cord Injury Interactive Telehealth for Wheelchair Users The Feasibility and Effects of Low-load Blood-flow Restricted Exercise Following Spinal Cord Injury Evaluation of a Power Assistance Device for Wheelchair-DUO Assessment of Vasomotion of People With Spinal Cord Injury Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion ExoAtlet II For SCI Patients Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO) Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue. Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit High-intensity Interval Training for Cardiometabolic Health in Persons With Spinal Cord Injury High-intensity Interval Training and Mixed Meal Responses in Persons With Spinal Cord Injury The ReWalk Exoskeletal Walking System for Persons With Paraplegia Gait Training for Individuals With Paraplegia Using the H-MEX Exoskeleton Training With Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion for Patients With Chronic Complete Paraplegia Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.

Brief Title

Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis

Official Title

Nebido® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia

Brief Summary

      Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to
      decreased bone mineral density resp osteoporosis. In this study bone mineral density is
      assessed in hypogonadal paraplegic patients, who are on standard prophylactic therapy for
      osteoporosis and and on a standard physiotherapy exercise program one group receiving Nebido
      for testosterone replacement (TRT). The additional effect of TRT on bone mineral density /
      osteoporosis is assessed (CT scan lumbar spine).

Study Type


Primary Outcome

Bone mineral density (CT lumbar spine)




Testosterone Undeconate (Nebido-R, BAY86-5037)

Study Arms / Comparison Groups

 Group 1


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2005

Completion Date

May 2009

Primary Completion Date

May 2009

Eligibility Criteria

        Inclusion Criteria:

          -  Male patients > 18yrs

          -  Osteoporosis prophylaxis/therapy with

               -  vitamin D 800 - 1200 mg per day,

               -  calcium 800 - 1000 mg per day,

               -  Fosamax 70 once a week.

          -  Standardised physiotherapy exercise programme.

          -  No proliferative bone disease.

          -  No history of calcium oxalate stones.

          -  No use of aromatase inhibitors.

          -  No use of 5-alpha reductase inhibitors.

        Nebido group:

          -  No contraindications to use of Nebido (known prostate or breast carcinoma or suspicion
             thereof, no past or present history of liver tumours);

          -  No known hypersensitivity to testosterone or excipients of Nebido

        Exclusion Criteria:

          -  Androgen dependent carcinoma of the prostate or male mammary gland, past or present
             history of liver tumours, hypersensitivity towards the active pharmaceutical
             ingredient or other ingredients.




18 Years - N/A

Accepts Healthy Volunteers



Bayer Study Director, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Study Sponsor


Study Sponsor

Bayer Study Director, Study Director, Bayer

Verification Date

April 2010